EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells

被引:0
作者
Shu-Jun Chen
Jing Luan
Hai-Shi Zhang
Can-Ping Ruan
Xin-Yun Xu
Qing-Quan Li
Nian-Hong Wang
机构
[1] Huashan Hospital,Department of Dermatology
[2] Fudan University,Department of Pathology
[3] Shanghai Medical College,Department of Rehabilitation Medicine
[4] Fudan University,undefined
[5] HuaShan Hospital,undefined
[6] Fudan University,undefined
来源
Molecular Biology Reports | 2012年 / 39卷
关键词
Multidrug resistance; EGFR; Cell cycle; CyclinD1; Breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Despite the improvement of strategies against cancer therapy, the multidrug resistance (MDR)is the critical problem for successful cancer therapy. Recurrent cancers after initial treatment with chemotherapy are generally refractory to second treatments with these anticancer therapies. Therefore, it is necessary to elucidate the therapy-resistant mechanism for development of effective therapeutic modalities against tumors. Here we demonstrate a phase-specific chemotherapy resistance due to epidermal growth factor receptor (EGFR) in human breast cancer cells. Thymidine-induced G1-arrested cultures showed upregulated chemosensitivity, whereas S-phase arrested cells were more resistant to chemotherapeutic agents. Overexpression of EGFR promoted the MDR phenotypes in breast cancer cells via accelerating the G1/S phase transition, whereas depletion of EGFR exerted the opposite effects. Furthermore, CyclinD1, a protein related to cell cycle, was demonstrated to be involved in above EGFR-mediated effects since EGFR increased the expression of CyclinD1, and the specific RNA interference against CyclinD1 could primarily abolish the EGFR-induced MDR phenotypes. These data provide new insights into the mode by which MDR breast cancers evade cytoxic attacks from chemotherapeutic agents and also suggest a role for EGFR-CyclinD1 axis in this process.
引用
收藏
页码:5465 / 5471
页数:6
相关论文
共 55 条
[1]  
Stavrovskaya AA(2000)Cellular mechanisms of multidrug resistance of tumor cells Biochemistry 65 95-106
[2]  
Eytan GD(2005)Mechanism of multidrug resistance in relation to passive membrane permeation Biomed Pharmacother 59 90-97
[3]  
Teodori E(2006)The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR) Curr Drug Targets 7 893-909
[4]  
Dei S(2005)The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin Exp Oncol 27 191-195
[5]  
Martelli C(2000)Influence of tumor drug resistance phenotype on the dynamics of cisplatin-induced changes of rat peripheral lymphocyte chromatin structure in Guerin’s carcinoma Tsitol Genet 34 11-17
[6]  
Scapecchi S(1999)Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells Clin Cancer Res 5 1876-1883
[7]  
Gualtieri F(1998)Inappropriate cell cycle progression enhances the induction of apoptosis by flavopiridol in Taxol treated gastric cancer cells Proc Am Assoc Cancer Res 39 190-2297
[8]  
Chekhun VF(2010)Establishment of a human hepatoma multidrug resistant cell line in vitro World J Gastroenterol 16 2291-2598
[9]  
Lukyanova NY(1987)Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin Cancer Res 47 2594-1774
[10]  
Yurchenko OV(2007)Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells Cancer Sci 98 1767-86